Othon Iliopoulos, MD
von Hippel-Lindau Disease/Familial Renal Cell Cancer Program
Massachusetts General Hospital Cancer Center
Associate Professor of Medicine
Harvard Medical School
Hematology & Medical Oncology
Center for Cancer Research
Explore the Iliopoulos Lab
The Iliopoulos laboratory works on the main mechanisms underlying the reprogramming of cancer cell metabolism and cancer angiogenesis with the goal to develop mechanism-based strategies for selectively killing cancer cells. We use Renal Cell Carcinoma (RCC) as a model disease of altered cancer metabolism and angiogenesis mechanisms. Cancer cells transform their metabolism to adapt to the needs of fast growth and to compete with the surrounding normal cells for nutrients and oxygen. In addition to a reprogrammed metabolism, cancer cells stimulate the growth of new blood vessels that bring blood to them, a phenomenon known for many years as “cancer angiogenesis”. The laboratory identifies and validates therapeutic targets that disrupt these processes.
Discovery and development of hypoxia inducible factor 2a (HIF2a) inhibitors for treatment of renal cell carcinoma and other HIF2a-dependent cancers
We screened libraries of chemical compounds and discovered chemical molecules that significantly and specifically decrease the expression of HIF2a (Zimmer M. et al. Molecular Cell 2008; 32(6): 838- 48). We used these HIF2a inhibitors as chemical biology probes and discovered that they suppress the expression of HIF2a by activating IRP1. We thus proved a crosstalk between the iron and oxygen sensing mechanisms within the cell. We demonstrated that the HIF2a inhibitors discovered are “active” and that they reverse the consequences of VHL protein loss (Metelo AM. Journal Clinical Investigation 2015; 125(5): 1987-97). Our chemical HIF2a inhibitors are very promising agents for treating RCC.
Targeting the metabolic reprogramming of RCC and HIF2a expressing tumors; from the lab to the bedside
We brought these fundamental observations of my laboratory on glutamine metabolism to the clinic. We initiated a Phase 1 trial with Glutaminase 1 (GLS1) inhibitors for patients with RCC and triple negative breast cancers nationwide. We are now opening a new clinical trial of GLS1 inhibitor CB-839 and PARP inhibitor combination treatment for patients with RCC, prostate, triple negative and ovarian cancer.
Modeling Renal Cell Carcinoma in the zebrafish
Zebrafish with homozygous inactivating mutations in VHL gene recapitulate aspects of the human VHL disease, including abnormal proliferation of their kidney epithelium. We are using the zebrafish as a model system to model the diverse pathways that lead to renal cell carcinoma development.
There is a post-doctoral position available in the laboratory of Othon Iliopoulos, MD, PhD at the Massachusetts General Hospital Cancer Center and Harvard Medical School. We study the molecular and metabolic effects of hypoxia on cancer cell metabolism and signaling, with a particular clinical interest in renal cell, ovarian and prostate cancer. The goal is to identify and validate novel strategies to target cancer metabolism. Specific projects related to this goal include identification of the signaling and epigenetic events induced by altered tumor metabolism, the role of VHL/HIF in tumor growth and metastasis, the molecular function of tumor suppressor genes mutated in renal cancer (such as VHL, FLCN, BAP1) and the role of driver mutations in the development of human hemangioblastomas.
The ideal candidate should have experience with molecular and/or metabolic techniques. Standard techniques in the lab include cell and molecular biology techniques. Knowledge of single-cell RNA sequencing and background in zebrafish and mouse models is advantageous but not required.
To apply, please send an email with CV and cover letter to: firstname.lastname@example.org
Okazaki A, Gameiro PA, Christodoulou D, Laviollette L, Schneider M, Chaves F, Stemmer-Rachamimov A, Yazinski SA, Lee R, Stephanopoulos G, Zou L, Iliopoulos O. Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers. J Clin Invest. 2017; 127(5): 1631-1645. (Research Highlights “Targeting metabolism in RCC” in Nature Reviews Nephrology. 13, 320 (2017).
Laviolette LA, Mermoud J, Calvo IA, Olson N, Boukhali M, Steinlein OK, Roider E, Sattler EC, Huang D, Teh BT, Motamedi M, Haas W, Iliopoulos O. Negative regulation of EGFR signalling by the human folliculin tumour suppressor protein. Nat Commun. 2017; 28;8: 15866.
Metelo AM, Noonan HR, Li X, Jin YN, Baker R, Kamentsky L, Zhang Y, van Rooijen E, Shin J, Carpenter AE, Yeh JR, Peterson RT, Iliopoulos O. Treatment of VHL disease phenotypes with small molecule HIF2a inhibitors. Journal Clinical Investigation 2015; 125 (5):1987-97.
Gameiro PA, Yang J, Metelo AM, Pérez-Carro R, Baker R, Wang Z, Arreola A, Rathmell WK, Olumi A, López-Larrubia P, Stephanopoulos G and Iliopoulos O. HIF mediated reductive carboxylation occurs in vivo through regulation of citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metabolism. 2013;17 (3): 372-385.
Metallo CM, Gameiro PA, Bell EL, Mattaini KR, Yang J, Hiller K, Jewell CM, Zachary R. Johnson JR, Irvine DJ, Guarente G, Kelleher JK, Vander Heiden MG, Iliopoulos O* and Gregory Stephanopoulos*. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia.Nature. 481 (7381):380-4, 2011 Nov 20.
Zimmer M, Ebert BL, Neil C, Brenner K, Papaioannou I, Melas A, Tolliday N, Lamb J, Pantopoulos K, Golub T, Iliopoulos O. Small-molecule inhibitors of HIF-2a translation link its 5'UTR iron-responsive element to oxygen sensing. Molecular Cell. 2008; 32(6): 838-48.
Expression of Hypoxia Inducible Factor HIF2a rewires the central carbon metabolism in renal cell cancer.
Learn more about the people working in our lab.
- Clinical Director, Von-Hippel Lindau Disease/Familial Renal Cell Cancer Program
- Tupa Basuroy, PhD
- Evmorphia Konstantakou, PhD
- Yun Liao, MD